Breaking Down Henan Lingrui Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) is a resilient mid-cap play or a risk-laden bet? In the quarter ended September 30, 2025 the company posted revenue of 942.16 million CNY, lifting TTM revenue to 3.78 billion CNY and supporting a market cap of 12.35 billion CNY (P/S 3.26); profitability remains strong with TTM net income of 799.61 million CNY, a net margin of 20.73% and ROE of 23.83%, while EPS of 1.40 CNY and a P/E of 15.39 sit alongside a 0.90 CNY annual dividend (4.17% yield); liquidity shows total cash of 862.57 million CNY and operating cash flow of 948.57 million CNY, but leverage is notable with a debt-to-equity of 2.66 and a current ratio of 1.01-valuation multiples such as EV/EBITDA at 14.59 and enterprise value of 11.03 billion CNY add context, and strategic growth moves like the planned 782 million CNY acquisition of Silver Valley Pharmaceutical plus over 20 provincial and national honors hint at upside-read on to unpack what these figures mean for investors

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Revenue Analysis

Key revenue metrics for Henan Lingrui Pharmaceutical Co., Ltd. highlight steady top-line growth, improving revenue productivity per employee, and a market valuation that reflects mid-cap status within the sector.

• Quarter (ending 2025-09-30) revenue: 942.16 million CNY - +10.44% vs prior quarter.
• Trailing Twelve Months (TTM) revenue as of 2025-09-30: 3.78 billion CNY - +6.15% YoY.
• Full-year 2024 revenue: 3.50 billion CNY - +5.72% vs 2023.
• Workforce: 2,435 employees; revenue per employee: ~1.55 million CNY.
• Market capitalization: 12.35 billion CNY; Price-to-Sales (P/S) ratio: 3.26.

Interpretation of these figures suggests a consistent but moderate revenue growth trajectory, with notable quarter-on-quarter acceleration in Q3 2025. Revenue per employee at ~1.55 million CNY indicates solid operational productivity relative to the company's scale. The P/S of 3.26 places market expectations at a premium over peers with lower growth, while a 12.35 billion CNY market cap situates the company in the mid-cap tier.

For context on strategic direction that may affect future revenue generation, see Mission Statement, Vision, & Core Values (2026) of Henan Lingrui Pharmaceutical Co., Ltd.

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Profitability Metrics

Key profitability indicators for Henan Lingrui Pharmaceutical over the trailing twelve months (TTM) illustrate solid margins, efficient operations and attractive shareholder returns.

• TTM Net Income: 799.61 million CNY
• Net Profit Margin: 20.73%
• Operating Margin: 23.46%
• ROA (Return on Assets): 9.12%
• ROE (Return on Equity): 23.83%
• EPS (Earnings Per Share): 1.40 CNY
• P/E Ratio: 15.39
• Annual Dividend per Share: 0.90 CNY - Dividend Yield: 4.17% (Ex-dividend date: 2025-06-20)
• Enterprise Value / EBITDA: 14.59

For context on corporate purpose and strategic direction, see: Mission Statement, Vision, & Core Values (2026) of Henan Lingrui Pharmaceutical Co., Ltd.

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Debt vs. Equity Structure

• Total Debt to Equity Ratio: 2.66 - a higher reliance on debt financing versus equity.
• Current Ratio: 1.01 - near the breakeven point for short-term liquidity.
• Book Value per Share: 5.85 CNY - net asset value attributable per share.
• Beta: 0.10 - significantly lower volatility relative to the market.
• Enterprise Value: 11.03 billion CNY - total company valuation including debt.
• Market Capitalization: 12.35 billion CNY; P/E Ratio: 15.39 - market-implied earnings multiple.

• High Debt-to-Equity (2.66) vs. modest Current Ratio (1.01) implies leverage amplifies returns but tightens liquidity - monitor interest coverage and debt maturities.
• Book value per share (5.85 CNY) offers a tangible floor; compare current share price to evaluate margin of safety.
• Low beta (0.10) suggests the stock may act defensively within a portfolio, though leverage can increase downside in stressed scenarios.
• Enterprise Value (11.03B CNY) relative to Market Cap (12.35B CNY) indicates net cash/debt position is modest; combine EV with operating metrics (EBIT/EBITDA) for valuation clarity.
• P/E of 15.39 positions the stock in a moderate valuation band - assess growth prospects and earnings quality to justify the multiple.

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Liquidity and Solvency

Key liquidity and solvency metrics for Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) highlight strong cash generation, ample cash on hand, and conservative market volatility.

• Total cash (as of 31-Mar-2025): 862.57 million CNY
• Cash per share: 1.52 CNY
• Operating cash flow (TTM): 948.57 million CNY
• Levered free cash flow (TTM): 486.06 million CNY
• Beta: 0.10
• Enterprise Value / Revenue: 3.35
• Enterprise Value / EBITDA: 14.59

Practical investor implications:

• Strong operating cash flow (948.57M CNY TTM) and positive levered FCF (486.06M CNY TTM) indicate robust internal cash generation and the ability to service debt, reinvest, or return capital.
• Cash reserves of 862.57M CNY (1.52 CNY/share) provide a buffer for short-term obligations and strategic flexibility.
• Low beta (0.10) suggests the stock historically moves less than broader markets, which may appeal to risk-averse investors.
• Valuation multiples (EV/Revenue 3.35x; EV/EBITDA 14.59x) should be compared with peers and sector averages to assess relative valuation and potential upside or downside.

For additional context on shareholder composition and buying trends, see: Exploring Henan Lingrui Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Valuation Analysis

Key trailing twelve months (TTM) metrics provide a snapshot of Henan Lingrui Pharmaceutical Co., Ltd.'s operating scale, profitability and per-share productivity:

• TTM revenue: 3.61 billion CNY (quarterly revenue growth: 12.30%).
• TTM net income: 748.99 million CNY (quarterly earnings growth: 13.90%).
• TTM EBITDA: 867.70 million CNY.
• TTM gross profit: 2.75 billion CNY.
• TTM EPS: 1.33 CNY (quarterly earnings growth: 13.90%).
• TTM revenue per share: 6.42 CNY.

From a valuation perspective, investors typically translate these operating figures into per-share and ratio-based signals. Using the implied shares outstanding (~562.3M), the reported EPS aligns with TTM net income (1.33 CNY × ~562.3M ≈ 748.99M CNY), validating internal consistency between per-share and aggregate figures.

• High gross margin (~76.2%) suggests strong pricing power or low cost of goods relative to revenue - a structural profitability advantage for the product mix.
• EBITDA margin (~24.0%) indicates solid operating cash-generation before non-cash and non-operating items; useful when comparing to peers or assessing enterprise value multiples.
• Net margin (~20.8%) is robust for the sector, implying efficient cost control and favorable tax/financial treatment in the period measured.

Practical valuation inputs investors should compute (using market data such as current market capitalization or share price) include:

• Price / Earnings (P/E) = Share price / 1.33 CNY (EPS).
• Enterprise Value / EBITDA = (Market cap + net debt) / 867.70M CNY.
• Price / Sales (P/S) = Market cap / 3.61B CNY or per-share: share price / 6.42 CNY.

For further company context and to connect operational history with these valuation metrics, see: Henan Lingrui Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Risk Factors

• Leverage risk: total debt to equity = 2.66 - a high reliance on debt that increases financial fixed-charge obligations and sensitivity to interest-rate moves.
• Liquidity pressure: current ratio = 1.01 - minimal short-term cushion to absorb sudden cash-flow needs or working-capital shocks.
• Market volatility: beta = 0.10 - historically low correlation with market swings, reducing systematic risk but potentially limiting upside in bull markets.
• Valuation vs. revenue: EV/Revenue = 3.35 - the market assigns a premium relative to top-line; downside in revenue growth could compress value materially.
• Valuation vs. operating earnings: EV/EBITDA = 14.59 - implies moderate expectations for operating cash generation; margin compression would hurt enterprise valuation.
• Equity valuation: market cap = 12.35 billion CNY and P/E = 15.39 - a middle-of-the-road earnings multiple that assumes steady profitability.

• Refinancing and interest-rate risk: with leverage at 2.66x, rising rates or tighter credit could increase interest expense and refinancing costs.
• Operational risk: current ratio ≈1.0 means delayed receivables, inventory build-up, or supply disruptions could force short-term borrowing or asset sales.
• Growth-dependence risk: valuation multiples (EV/Revenue 3.35, EV/EBITDA 14.59) price in continued revenue and margin performance; miss targets → multiple contraction.
• Liquidity-event risk for shareholders: low beta may reduce headline volatility but does not immunize shares from idiosyncratic shocks tied to firm-specific leverage or earnings surprises.
• Market-perception risk: a P/E of 15.39 positions the stock neither deeply discounted nor richly valued - perception shifts can move the multiple quickly.

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Growth Opportunities

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) is positioning for mid-to-long-term growth through targeted M&A, capability-building in innovative drug R&D, and institutional recognition that supports scale and market credibility.

• Strategic acquisition: In December 2024 the company announced plans to acquire Silver Valley Pharmaceutical for approximately 782 million CNY to enter the chemical innovative drug market, broadening product mix and R&D capability.
• Profitability leverage: Management projects that the Silver Valley deal will enhance sustainable profitability via higher-margin innovative drug sales and potential pipeline monetization (deal value: 782,000,000 CNY).
• Reputation and competitive positioning: Over 20 provincial and national recognitions, including 'National Key High‑tech Enterprise' and 'National Intelligent Manufacturing Digital Factory', strengthen partner, payer and regulatory confidence.
• R&D infrastructure: Establishment of the Henan Provincial Institute of Modernized Traditional Chinese Medicine Industry and the Provincial Key Laboratory of Transdermal Drug Delivery Preparations enhances in‑house formulation and translational capability.
• Governmental endorsement: Designated a 'National Technology Innovation Demonstration Enterprise' by the Ministry of Industry and Information Technology, improving access to supportive policies and funding channels.

• Commercialization pathways: Internal R&D + acquired assets create multiple value levers - faster time-to-market for innovative drugs, licensing or co-development deals, and improved product mix.
• Operational synergies: Intelligent manufacturing recognition and digital factory status support capacity scaling and cost control as higher-margin products are introduced.
• Collaboration and funding: Institutional labs and the Innovation Consortium increase chances for government grants, academic partnerships, and talent attraction critical to biotech growth.

Further context on shareholder composition and investor activity is available here: Exploring Henan Lingrui Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?